vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and NextPlat Corp (NXPL). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $12.8M, roughly 1.3× NextPlat Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -40.2%, a 32.4% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -21.1%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -14.4%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
DERM vs NXPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $12.8M |
| Net Profit | $-1.2M | $-5.1M |
| Gross Margin | — | 14.3% |
| Operating Margin | -2.8% | -28.9% |
| Net Margin | -7.8% | -40.2% |
| Revenue YoY | 27.3% | -21.1% |
| Net Profit YoY | -182.0% | -70.6% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $12.8M | ||
| Q3 25 | $17.0M | $13.8M | ||
| Q2 25 | $15.0M | $13.2M | ||
| Q1 25 | $13.1M | $14.5M | ||
| Q4 24 | $12.6M | $16.2M | ||
| Q3 24 | $14.6M | $15.4M | ||
| Q2 24 | $14.9M | $17.0M | ||
| Q1 24 | $13.0M | $17.5M |
| Q4 25 | $-1.2M | $-5.1M | ||
| Q3 25 | $-2.3M | $-2.2M | ||
| Q2 25 | $-3.8M | $-1.8M | ||
| Q1 25 | $-4.1M | $-1.3M | ||
| Q4 24 | $1.5M | $-3.0M | ||
| Q3 24 | $-2.4M | $-4.2M | ||
| Q2 24 | $-3.4M | $-5.3M | ||
| Q1 24 | $-10.4M | $-1.5M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 19.9% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | 82.3% | 16.8% | ||
| Q3 24 | 63.9% | 23.2% | ||
| Q2 24 | 56.0% | 34.5% | ||
| Q1 24 | 47.7% | 27.8% |
| Q4 25 | -2.8% | -28.9% | ||
| Q3 25 | -9.0% | -14.5% | ||
| Q2 25 | -19.2% | -13.8% | ||
| Q1 25 | -25.3% | -10.2% | ||
| Q4 24 | 17.7% | -14.1% | ||
| Q3 24 | -19.8% | -52.1% | ||
| Q2 24 | -19.7% | -64.1% | ||
| Q1 24 | -77.4% | -10.5% |
| Q4 25 | -7.8% | -40.2% | ||
| Q3 25 | -13.6% | -15.9% | ||
| Q2 25 | -25.3% | -13.5% | ||
| Q1 25 | -31.0% | -9.2% | ||
| Q4 24 | 12.1% | -18.6% | ||
| Q3 24 | -16.3% | -27.4% | ||
| Q2 24 | -22.6% | -31.3% | ||
| Q1 24 | -80.1% | -8.5% |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.18 | $-0.05 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $-0.12 | $-0.22 | ||
| Q2 24 | $-0.17 | — | ||
| Q1 24 | $-0.53 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $13.7M |
| Total DebtLower is stronger | $25.3M | $1.3M |
| Stockholders' EquityBook value | $31.9M | $17.3M |
| Total Assets | $94.6M | $27.5M |
| Debt / EquityLower = less leverage | 0.79× | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $13.7M | ||
| Q3 25 | $24.9M | $13.9M | ||
| Q2 25 | $20.3M | $16.6M | ||
| Q1 25 | $21.1M | $17.7M | ||
| Q4 24 | $20.3M | $20.0M | ||
| Q3 24 | $22.5M | $20.4M | ||
| Q2 24 | $23.9M | $24.9M | ||
| Q1 24 | $24.1M | $23.5M |
| Q4 25 | $25.3M | $1.3M | ||
| Q3 25 | $25.2M | $1.2M | ||
| Q2 25 | $25.1M | $1.2M | ||
| Q1 25 | $25.0M | $1.3M | ||
| Q4 24 | $24.9M | $1.4M | ||
| Q3 24 | $19.8M | $1.5M | ||
| Q2 24 | $19.7M | $1.3M | ||
| Q1 24 | $14.7M | $1.4M |
| Q4 25 | $31.9M | $17.3M | ||
| Q3 25 | $25.9M | $21.4M | ||
| Q2 25 | $19.2M | $23.5M | ||
| Q1 25 | $21.5M | $25.3M | ||
| Q4 24 | $20.1M | $27.3M | ||
| Q3 24 | $10.9M | $22.5M | ||
| Q2 24 | $11.3M | $26.5M | ||
| Q1 24 | $13.0M | $31.2M |
| Q4 25 | $94.6M | $27.5M | ||
| Q3 25 | $85.2M | $30.0M | ||
| Q2 25 | $81.2M | $31.0M | ||
| Q1 25 | $85.0M | $35.2M | ||
| Q4 24 | $80.2M | $37.1M | ||
| Q3 24 | $64.0M | $41.1M | ||
| Q2 24 | $65.2M | $51.5M | ||
| Q1 24 | $66.6M | $65.1M |
| Q4 25 | 0.79× | 0.07× | ||
| Q3 25 | 0.97× | 0.05× | ||
| Q2 25 | 1.30× | 0.05× | ||
| Q1 25 | 1.16× | 0.05× | ||
| Q4 24 | 1.24× | 0.05× | ||
| Q3 24 | 1.81× | 0.07× | ||
| Q2 24 | 1.75× | 0.05× | ||
| Q1 24 | 1.13× | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-302.0K |
| Free Cash FlowOCF − Capex | — | $-339.0K |
| FCF MarginFCF / Revenue | — | -2.6% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-302.0K | ||
| Q3 25 | $-2.4M | $-2.7M | ||
| Q2 25 | $-942.0K | $-1.0M | ||
| Q1 25 | $-2.8M | $-2.1M | ||
| Q4 24 | $2.2M | $-476.0K | ||
| Q3 24 | $-1.2M | $-4.6M | ||
| Q2 24 | $-5.2M | $2.3M | ||
| Q1 24 | $-5.0M | $-2.7M |
| Q4 25 | — | $-339.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | $-508.0K | ||
| Q3 24 | — | $-4.7M | ||
| Q2 24 | — | $2.2M | ||
| Q1 24 | — | $-2.7M |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -8.0% | ||
| Q1 25 | — | -14.3% | ||
| Q4 24 | — | -3.1% | ||
| Q3 24 | — | -30.6% | ||
| Q2 24 | — | 13.2% | ||
| Q1 24 | — | -15.7% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
